Page last updated: 2024-09-03

blonanserin and Basal Ganglia Diseases

blonanserin has been researched along with Basal Ganglia Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Inoue, Y; Nakamura, H; Tsuchimori, K	1
Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A	1
Hamuro, A; Saito, S	1

Reviews

1 review(s) available for blonanserin and Basal Ganglia Diseases

Article	Year
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. Journal of pharmacological sciences, 2021, Volume: 145, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Child; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Product Surveillance, Postmarketing; Safety; Schizophrenia; Treatment Outcome; Young Adult	2021

Article

Year

Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.

Journal of pharmacological sciences, 2021, Volume: 145, Issue:1

Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Child; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Product Surveillance, Postmarketing; Safety; Schizophrenia; Treatment Outcome; Young Adult

2021

Trials

1 trial(s) available for blonanserin and Basal Ganglia Diseases

Article	Year
Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2010, Volume: 10, Issue:4 Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Japan; Male; Mental Disorders; Mental Status Schedule; Neuropsychological Tests; Piperazines; Piperidines; Prospective Studies; Psychometrics; Receptor, Serotonin, 5-HT2A; Treatment Outcome	2010

Article

Year

Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2010, Volume: 10, Issue:4

Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Japan; Male; Mental Disorders; Mental Status Schedule; Neuropsychological Tests; Piperazines; Piperidines; Prospective Studies; Psychometrics; Receptor, Serotonin, 5-HT2A; Treatment Outcome

2010

Other Studies

1 other study(ies) available for blonanserin and Basal Ganglia Diseases

Article	Year
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin. Pharmacology, biochemistry, and behavior, 2015, Volume: 138 Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines	2015

Article

Year

Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.

Pharmacology, biochemistry, and behavior, 2015, Volume: 138

Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines

2015